NCT07238062Available不适用
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Multiple System Atrophy."
Hope Biosciences Research Foundation2 个研究点 分布在 1 个国家开始时间: 2025年11月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- 试验地点
- 2
研究概览
简要总结
This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass pre-screening and a completed screening. The subjects will receive 12 intravenous infusions of HB-adMSCs and 6 intrathecal injections of HB-adMSCs over the course of 44 weeks (1 infusion each month and 1 injection every other month).
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female participants 18-85 years of age
- •Participants must have a diagnosis of "Clinically Established" or "Clinically Probable" MSA.
- •Participants must have at least one brain MRI marker suggestive of MSA.
- •Participants must have both autonomic failure and either poorly L-dopa-responsive parkinsonism or cerebellar ataxia.
- •Female participants of childbearing potential should not be pregnant or plan to become pregnant during protocol participation and for 6 months after the last investigational product administration. Female participants of childbearing potential should confirm the use of one of the following contraceptive measures:
- •Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal).
- •Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS).
- •Barrier contraceptive methods (condoms, diaphragm, etc.).
- •Surgery (occlusion bilateral tubal ligation, hysterectomy, vasectomized partner).
- •Male participants if their sexual partners can become pregnant should ensure the use one of the following methods of contraception during protocol participation and for 6 months after the last administration of the investigated product:
- •Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal).
- •Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS).
- •Barrier contraceptive methods (condoms, diaphragm, etc.).
- •Surgery (vasectomy, occlusion bilateral tubal ligation (partner), hysterectomy (partner)).
- •Participants should be able to read, understand, and to provide voluntary consent.
排除标准
- •Women who are currently pregnant or lactating.
- •The participant has any active infection requiring medications per PI's discretion.
- •The participant has any clinical signs or symptoms of infection per PI's discretion.
- •The participant has hyperthermia or hypothermia.
- •The participant has any known recent (within the last 6 months) coagulation anomalies that are not being medically treated and are not stable per PI's discretion.
- •The participant has any abnormal laboratory values at the screening visit which the Investigator determines to be clinically significant and make the patient unsuitable for participation.
- •The Investigator determines the patient to be unsuitable for participation for other reasons, such as, but not limited to deep vein thrombosis (DVT), pulmonary embolus, cardiac arrhythmia, or those who have a prothrombotic condition, or who require persistent oxygen supplementation.
- •The participant has a substantial and persistent response to dopaminergic medications.
- •The participant has unexplained anosmia.
- •The participant has fluctuating cognition, early dementia, or hallucinations.
- •The participant has certain eye movement abnormalities.
- •The participant has any MRI findings that suggest an alternative diagnosis.
研究者
研究点 (2)
Loading locations...
相似试验
Available
不适用
Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain InjuryBrain InjuryNCT07164482Hope Biosciences Research Foundation
Unknown
不适用
Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's DiseaseParkinson DiseaseNCT06056427Hope Biosciences Research Foundation
Approved For Marketing
不适用
Intermediate-Size Patient Population Expanded Access Program for Intravenous DifelikefalinUremic PruritusNCT05031546Cara Therapeutics, Inc.
Unknown
不适用
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 SyndromePost COVID-19 SyndromeNCT04798066Hope Biosciences Research Foundation
Available
不适用
Expanded Access to Ensartinib for Participants With ALK+ NSCLCALK Gene Rearrangement PositiveNon-Small Cell Lung CancerNCT04146571Xcovery Holdings, Inc.